Home › Research › Lewy body dementia
Clinical Phenotype of Apoe Ɛ4 Carriers In Patients With Vascular Dementia: A Cross-Sectional Study From Indonesia
Gunadi SGA, Fitrah YA, Soraya GV, Jannah AR, Sompa AW, Basri MI, Limoa LT, Hara N et al.. F1000Res, 2026-09-02
Topic: Genetics and APOE
Plain-language summary
Background Vascular dementia (VaD) is the second most common cause of dementia and exhibits substantial heterogeneity in cognitive, functional, and radiological manifestations. Despite the observed differences in clinical presentation, the factors responsible for this variability have not been clearly identified. While the apolipoprotein E ( APOE ) ε4 allele is widely known to increase the risk of Alzheimer’s disease, its contribution to the manifestation of VaD symptoms remains inadequately explored, particularly in Southeast Asian populations. This study was conducted to describe the clinical characteristics of APOE ε4 carriers with VaD and evaluate how they differ from individuals without the allele. Methods A cross-sectional approach was applied in this study to evaluate patients with VaD diagnosed according to the NINDS-AIREN criteria and Hachinski Ischemic Score. The evaluation covered cognitive function, dementia severity, and functional independence using MoCA-INA, CDR, ADL, and IADL instruments. Results were considered significant when p < 0.05. Results Sixteen patients with VaD were enrolled, including six APOE ε4 carriers and ten non-carriers. APOE ε4 carriers demonstrated significantly lower MoCA-INA scores than non-carriers (10.50 ± 5.39 vs. 18.80 ± 5.43; p = 0.010). Carriers also exhibited higher proportions of moderate-to-severe dementia, lower ADL and IADL scores, and a higher prevalence of cerebral atrophy, although these differences were not statistically significant (CDR, p = 0.263; ADL, p = 0.263; IADL, p = 0.082). Conclusions This study demonstrated that APOE4 carrier status was associated with lower MoCA-INA scores in this small VaD cohort. Differences in dementia severity, functional status, and cerebral atrophy were directionally worse among carriers but did note reach statistical difference.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gunadi, S. G. A., Fitrah, Y. A., Soraya, G. V., Jannah, A. R., Sompa, A. W., Basri, M. I., et al. (2026). Clinical Phenotype of Apoe Ɛ4 Carriers In Patients With Vascular Dementia: A Cross-Sectional Study From Indonesia. F1000Res. https://doi.org/10.12688/f1000research.188901.1
Vancouver
Gunadi SGA, Fitrah YA, Soraya GV, Jannah AR, Sompa AW, Basri MI, et al. Clinical Phenotype of Apoe Ɛ4 Carriers In Patients With Vascular Dementia: A Cross-Sectional Study From Indonesia. F1000Res. 2026. doi:10.12688/f1000research.188901.1.
BibTeX
@article{gunadi2026-88426919,
author = {Gunadi, S. G. A. and Fitrah, Y. A. and Soraya, G. V. and Jannah, A. R. and Sompa, A. W. and Basri, M. I. and Limoa, L. T. and Hara, N. and others},
title = {{Clinical Phenotype of Apoe Ɛ4 Carriers In Patients With Vascular Dementia: A Cross-Sectional Study From Indonesia}},
journal = {F1000Res},
year = {2026},
doi = {10.12688/f1000research.188901.1},
url = {https://doi.org/10.12688/f1000research.188901.1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results were considered significant when p < 0.05.
- Results Sixteen patients with VaD were enrolled, including six APOE ε4 carriers and ten non-carriers.
- APOE ε4 carriers demonstrated significantly lower MoCA-INA scores than non-carriers (10.50 ± 5.39 vs. 18.80 ± 5.43; p = 0.010).
- Carriers also exhibited higher proportions of moderate-to-severe dementia, lower ADL and IADL scores, and a higher prevalence of cerebral atrophy, although these differences were not statistically significant (CDR, p = 0.263; ADL, p = 0.263; IADL, p = 0.082).
- Conclusions This study demonstrated that APOE4 carrier status was associated with lower MoCA-INA scores in this small VaD cohort.
Study details
- Study designcross-sectional
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 30 of the 58 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (F1000Res) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 30 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 30 of the 58 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Lewy body dementia from nearby years
Also tagged “apoe2”
265 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.